Clearance of interstitial fluid (ISF) and CSF (CLIC) group‐part of Vascular Professional Interest Area (PIA), updates in 2022‐2023. Cerebrovascular disease and the failure of elimination of Amyloid‐β from the brain and retina with age and Alzheimer's disease: Opportunities for therapy

Kelly, Louise and Brown, Christopher and Michalik, Daniel and Hawkes, Cheryl A. and Aldea, Roxana and Agarwal, Nivedita and Salib, Rami and Alzetani, Aiman and Ethell, Douglas W and Counts, Scott E. and de Leon, Mony and Fossati, Silvia and Koronyo‐Hamaoui, Maya and Piazza, Fabrizio and Rich, Steven A. and Wolters, Frank J. and Snyder, Heather and Ismail, Ozama and Elahi, Fanny and Proulx, Steven T. and Verma, Ajay and Wunderlich, Hilary and Haack, Mareike and Dodart, Jean Cosme and Mazer, Norman and Carare, Roxana O. (2024) Clearance of interstitial fluid (ISF) and CSF (CLIC) group‐part of Vascular Professional Interest Area (PIA), updates in 2022‐2023. Cerebrovascular disease and the failure of elimination of Amyloid‐β from the brain and retina with age and Alzheimer's disease: Opportunities for therapy. Alzheimer's and Dementia : the journal of the Alzheimer's Association, 20 (2). pp. 1421-1435. ISSN 1552-5260

Abstract

This editorial summarizes advances from the Clearance of Interstitial Fluid and Cerebrospinal Fluid (CLIC) group, within the Vascular Professional Interest Area (PIA) of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART). The overarching objectives of the CLIC group are to: (1) understand the age‐related physiology changes that underlie impaired clearance of interstitial fluid (ISF) and cerebrospinal fluid (CSF) (CLIC); (2) understand the cellular and molecular mechanisms underlying intramural periarterial drainage (IPAD) in the brain; (3) establish novel diagnostic tests for Alzheimer's disease (AD), cerebral amyloid angiopathy (CAA), retinal amyloid vasculopathy, amyloid‐related imaging abnormalities (ARIA) of spontaneous and iatrogenic CAA‐related inflammation (CAA‐ri), and vasomotion; and (4) establish novel therapies that facilitate IPAD to eliminate amyloid β (Aβ) from the aging brain and retina, to prevent or reduce AD and CAA pathology and ARIA side events associated with AD immunotherapy.